拓扑替康对人卵巢癌细胞株端粒酶活性表达的影响

目的 :探讨拓扑替康对卵巢癌细胞端粒酶活性表达的影响。方法 :用TRAP ELISA法检测浓度为 2 60 0 0 μg·L-1 的盐酸拓扑替康 (和美新 )作用于卵巢癌HO 8910细胞株不同时间后端粒酶活性的改变 ,并以流式细胞检测法同步检测细胞凋亡及细胞周期改变。结果 :随着拓扑替康作用时间的延长 ,HO -8910细胞株的凋亡率逐渐增加 ,而端粒酶活性逐渐降低。当作用达 60h后 ,细胞凋亡达 47.62 %时端粒酶活性呈阴性。结论 :端粒酶活性抑制不是拓扑替康诱导卵巢癌细胞凋亡的直接原因 ,但临床监测端粒酶活性表达有助于对盐酸拓扑替康抗卵巢癌的疗效进行客观评价。

Effect of topotecan on telomerase activity expression in human ovarian cancer cell line HO-8910

Objective To evaluate the effect of topotecan on telomerase activity expression in human ovarian cancer cells. Methods TRAP-ELISA assay was used to study the changes of telomerase of HO-8910 cell line activated by topotecan hydrochloride after different period, and flow cytometry method was applied to detect the cell apoptosis and the changes of cell cycle in the same time.Results The apoptosis rate of HO-8910 cell line rose gradually, while telomerase activity reduced progressively along with the activating time. The telomerase activity was completely inhibited while the cell apoptosis reached 47.62% after 60 hours. Conclusions The inhibition of telomerase activity does not directly result from apoptosis induced by chemotherapeutic drug topotecan in ovarian cancer treatment. Measuring telomerase activity can be the clinical index in objectively evaluating the curative effect of topotecan.